1. Market Research
  2. > mondoBIOTECH Holding AG - Product Pipeline Review - 2013

mondoBIOTECH Holding AG - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

mondoBIOTECH Holding AG - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Mondobiotech Holding AG - Product Pipeline Review - 2013” provides data on the Mondobiotech Holding AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mondobiotech Holding AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Mondobiotech Holding AG and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Mondobiotech Holding AG - Brief Mondobiotech Holding AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mondobiotech Holding AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mondobiotech Holding AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mondobiotech Holding AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Mondobiotech Holding AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mondobiotech Holding AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mondobiotech Holding AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mondobiotech Holding AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mondobiotech Holding AG and identify potential opportunities in those areas.

Table Of Contents

mondoBIOTECH Holding AG - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 5
List of Figures 5
mondoBIOTECH Holding AG Snapshot 6
mondoBIOTECH Holding AG Overview 6
Key Information 6
Key Facts 6
mondoBIOTECH Holding AG - Research and Development Overview 7
Key Therapeutic Areas 7
mondoBIOTECH Holding AG - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
mondoBIOTECH Holding AG - Pipeline Products Glance 12
mondoBIOTECH Holding AG Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
mondoBIOTECH Holding AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
mondoBIOTECH Holding AG - Drug Profiles 16
DasKloster 0228-01 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DasKloster-001401 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
DasKloster-003901 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
DasKloster-008001 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
DasKloster-014101 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
DasKloster-018201 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
DasKloster-021001 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
DasKloster-024701 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
DasKloster-024901 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DasKloster-027401 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
DasKloster-050101 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
DasKloster-1000-01 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
DasKloster-1000-02 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DasKloster-1000-04 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
DasKloster-100003 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
interferon gamma-1b 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
secretin 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
thymopentin 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
mondoBIOTECH Holding AG - Pipeline Analysis 36
mondoBIOTECH Holding AG - Pipeline Products by Therapeutic Class 36
mondoBIOTECH Holding AG - Pipeline Products by Route of Administration 38
mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action 39
mondoBIOTECH Holding AG - Recent Pipeline Updates 41
mondoBIOTECH Holding AG - Dormant Projects 42
mondoBIOTECH Holding AG - Company Statement 43
mondoBIOTECH Holding AG - Locations And Subsidiaries 45
Head Office 45
Other Locations and Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables


mondoBIOTECH Holding AG, Key Information 6
mondoBIOTECH Holding AG, Key Facts 6
mondoBIOTECH Holding AG - Pipeline by Indication, 2013 9
mondoBIOTECH Holding AG - Pipeline by Stage of Development, 2013 10
mondoBIOTECH Holding AG - Monotherapy Products in Pipeline, 2013 11
mondoBIOTECH Holding AG - Phase II, 2013 12
mondoBIOTECH Holding AG - Phase I, 2013 13
mondoBIOTECH Holding AG - Preclinical, 2013 14
mondoBIOTECH Holding AG - Discovery, 2013 15
mondoBIOTECH Holding AG - Pipeline By Therapeutic Class, 2013 37
mondoBIOTECH Holding AG - Pipeline By Route of Administration, 2013 38
mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action, 2013 40
mondoBIOTECH Holding AG - Recent Pipeline Updates, 2013 41
mondoBIOTECH Holding AG - Dormant Developmental Projects,2013 42
mondoBIOTECH Holding AG, Subsidiaries 45

List of Figures


mondoBIOTECH Holding AG - Pipeline by Indication, 2013 8
mondoBIOTECH Holding AG - Pipeline by Stage of Development, 2013 10
mondoBIOTECH Holding AG - Monotherapy Products in Pipeline, 2013 11
mondoBIOTECH Holding AG - Pipeline By Therapeutic Class, 2013 36
mondoBIOTECH Holding AG - Pipeline By Route of Administration, 2013 38
mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action, 2013 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.